chiglitazar sodium + venetoclax + azacitidine

CVA is an experimental triple combination regimen consisting of chiglitazar sodium, venetoclax, and azacitidine, currently under investigation for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). Chiglitazar sodium is a novel pan-peroxisome proliferator-activated receptor (PPAR) agonist that targets PPARα, PPARγ, and PPARδ, potentially sensitizing leukemia cells to apoptosis. Venetoclax is a selective small-molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), which is frequently overexpressed in AML cells to evade programmed cell death. Azacitidine is a hypomethylating agent that acts as a DNA methyltransferase inhibitor, promoting the re-expression of tumor suppressor genes and inducing cell differentiation. This combination therapy aims to achieve synergistic anti-leukemic effects by simultaneously targeting epigenetic regulation, apoptotic pathways, and metabolic/differentiation signaling in resistant leukemia cell populations.